Michael Duruisseaux: Mechanisms of resistance to KRASG12C inhibitors in non-small cell lung cancer

Michael Duruisseaux posted on X about recent paper by him as co-author titled “Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer” published on Frontiers in Oncology.

Authors: Ali Chour, Anne-Claire Toffart, Elodie Berton, Michael Duruisseaux.

“Please to share our last work ‘Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer'”

Source: Michael Duruisseaux/X

Dr. Michael Duruisseaux coordinates the general and orphan thoracic oncology team in the pneumology department at Louis Pradel Hospital (Hospices Civils de Lyon) and serves as the medical director of the Joint Research Unit in Thoracic Oncology. He is also a physician-scientist in the OncoPharmacology team at the Lyon Cancer Research Center, where he leads a research group focused on thoracic oncology and pharmacology.